2002年12月
Prothrombin levels in newborn infants by the carinactivase-1 method
SEMINARS IN THROMBOSIS AND HEMOSTASIS
- ,
- ,
- ,
- ,
- ,
- 巻
- 28
- 号
- 6
- 開始ページ
- 539
- 終了ページ
- 543
- 記述言語
- 英語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.1055/s-2002-36698
- 出版者・発行元
- THIEME MEDICAL PUBL INC
A recently developed method to quantitate prothrombin in plasma uses the carinactivase-1 (CA-1) method. The present study was designed to establish the reference value by the CA-1 method in the neonatal period and to explore the effect of gestational age, birth weight, concurrent diseases, and vitamin K administration on the prothrombin levels. We enrolled 78 consecutive neonates. The gestational ages ranged from 28 to 41 weeks, and the birth weight ranged from 850 to 3750 g. Twenty-nine infants had concurrent diseases, and the others (n = 49) were healthy. A 300 muL blood sample was drawn into a plastic syringe containing 60 U freeze-dried buffered heparin. Prothrombin levels did not differ between appropriate-for-date (AFD) and light-for-date (LFD) babies (p = 0.090) or between groups with and without concurrent diseases (p = 0.210). In healthy AFD babies, prothrombin levels correlated with gestational age (r = 0.465, p = 0.003) and birth weight (r = 0.458, p = 0.003). In healthy low-birth-weight infants (n = 14) and those with concurrent diseases (n = 17), the changes after vitamin K administration were not significant. The CA-1 method is of clinical use in monitoring coagulation during the early neonatal period.
- リンク情報
- ID情報
-
- DOI : 10.1055/s-2002-36698
- ISSN : 0094-6176
- PubMed ID : 12536347
- Web of Science ID : WOS:000180104500011